Insights Into Multiple Myeloma (MM)

Perspectives on current treatment practices regarding frontline therapy of MM, the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents

Southeast – March 10, 2023

Faculty Chair

Jonathan Kaufman, MD

Winship Cancer Institute, Atlanta, GA, USA

Central – April 22, 2023

Faculty Chair

Hans Lee, MD

MD Anderson Cancer Center, Houston, TX, USA

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Dallas, TX
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of MM
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.